"It stops the amyloid beta oligomer buildup, and also stops the consequences of neuroinflammation, which causes a lot of damage in the brain. So, the drug is very powerful on two levels ...

Experimental drug NU-9—a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials ...

“It stops the amyloid beta oligomer buildup, and also stops the consequences of neuroinflammation, which causes a lot of damage in the brain. So, the drug is very powerful on two ...

"It stops the amyloid beta oligomer buildup, and also stops the consequences of neuroinflammation, which causes a lot of damage in the brain. So, the drug is very powerful on two levels ...

The therapies encourage cleaning cells called microglia to attack the clumps of amyloid-beta proteins that are thought to be involved in neurodegeneration. Microglia responses to amyloid beta can lead ...

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/OD), during the ‘Abeta Targeting Therapies in AD’ symposium on 3 April, Roche presented interim trial data for ...

CD47 is found to play a pivotal role in this immunosuppression by inducing the production of amyloid-β (Aβ), which interacts with CD74 on B cells, leading to B-cell suppression and subsequent adaptive ...

Beta-blockers can treat a variety of conditions including diabetes. They might cause certain side effects such as headaches and fatigue. People with diabetes tend to develop heart disease or ...

PMN310 is uniquely designed to selectively target toxic oligomers of amyloid-beta, which we believe is ... Aß vaccine program in AD based on its oligomer target epitope(s). ProMIS will present ...